Atrial natriuretic factor improves renal function and lowers systolic blood pressure in renal allograft recipients treated with cyclosporin A.
OBJECTIVE
Atrial natriuretic factor (ANF) has several properties which suggest that it may ameliorate cyclosporin A nephrotoxicity. We therefore investigated the response to a pharmacological dose of ANF in renal transplant recipients treated with cyclosporin A.


METHODS
A single-blind randomized crossover design comparing the renal and haemodynamic effects of D-glucose (placebo) with ANF.


METHODS
Seven patients with stable renal function following renal transplantation were studied under maximal water diuresis. Glomerular filtration rate and effective renal plasma flow were estimated from clearances of inulin and para-aminohippurate, respectively.


RESULTS
Plasma ANF levels increased significantly in association with increased diuresis and natriuresis. Glomerular filtration rate was unchanged after placebo but increased significantly after ANF fusion. Likewise, effective renal plasma flow increased significantly with ANF infusion. There was a significant fall in systolic blood pressure, with no apparent change in heart rate and diastolic blood pressure.


CONCLUSIONS
These results suggest that ANF may have beneficial effects in protecting against cyclosporin A-induced nephrotoxicity and hypertension.
Lang
C C
CC
Department of Clinical Pharmacology, Ninewells Hospital and Medical School, Dundee, UK.
Henderson
I S
IS
Mactier
R
R
Stewart
W K
WK
Struthers
A D
AD
D009320:Atrial Natriuretic Factor / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007668:Kidney / Q000187:drug effects*; D007677:Kidney Function Tests; D016030:Kidney Transplantation / Q000502:physiology*; D008875:Middle Aged; D012079:Renal Circulation / Q000187:drug effects; D016037:Single-Blind Method
D016572:Cyclosporine; D009320:Atrial Natriuretic Factor